Head-to-head · WeighScore
Vida Health vs Zealthy
The verdict
Vida Health takes it — 55.2/100 to 46.7/100.
Vida Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Vida Health is a virtual chronic-care platform whose Medical Weight Loss program prescribes anti-obesity medications such as GLP-1s, combined with behavioral-health coaching and medical management.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Vida Health | Zealthy |
|---|---|---|
| WeighScore | 55.2/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #446 | #496 |
| Semaglutide | Not disclosed | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | Not disclosed | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | Coverage not published | 34 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #446 · C
Strengths
- Medical Weight Loss program includes anti-obesity GLP-1 medications
- Pairs medication with behavioral-health coaching and medical management
- Whole-person care across chronic conditions, sleep, and nutrition
- Integrates with major health plans, PBMs, and benefit platforms
- Established virtual chronic-care platform
Where it loses points
- Distributed mainly via employers and health plans, not direct cash-pay
- Access usually requires employer or plan sponsorship
- No public consumer GLP-1 pricing
- Clinician credentials not detailed publicly
- Less suited to consumers wanting direct-to-door GLP-1
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.